Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13354MR)

This product GTTS-WQ13354MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13354MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7383MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ9694MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ13122MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ10418MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY2439821
GTTS-WQ4141MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-754091
GTTS-WQ11887MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-0264
GTTS-WQ8059MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ5168MR IVTScrip™ mRNA-Anti-Canlupfam IL31, CAN34D3-65(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CAN34D3-65
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW